Hollister Biosciences Inc. Provides Update on Q3 2020 Performance

0
19

 

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 80 dispensaries throughout Arizona, is pleased to provide an update on its Q3, 2020 performance.

Q3 2020 Update

For the period beginning July 1st, 2020 and ending September 30th, 2020, Hollister reports that it generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our ability to deliver record quarterly revenue in such a challenging market environment. We attribute our revenue growth to further penetration of the California and Arizona dispensary networks and successful new product launches with our joint venture partners.  We hope to continue this positive momentum into year-end” stated Carl Saling, CEO.

LEAVE A REPLY

Please enter your comment!
Please enter your name here